---
document_datetime: 2023-09-21 17:30:01
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-hexal-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-hexal-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4086906
conversion_datetime: 2025-12-22 08:08:34.106244
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel Hexal

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on longer   | Product Information affected 3   | Summary   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------|----------------------------------|-----------|
| IB/0009 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                       | 22/07/2011                          | n/a no                                             | SPC                              |           |
| IB/0008 | According to CHMP communication from 02 December 2010 amendments are introduced in the Summary of Product Characteristics (SmPC) and the Package Leaflet (PL) to update sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precaution for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic | 12/05/2011 product                  | n/a                                                | SPC, Annex II, PL                |           |

1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures.

2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes.

3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0) 20 7523 7455

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                              |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------|
|          | properties\" of clopidorel/acetylsalicylic acid (ASA) of the SmPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Minor linguistic changes have been introduced in the product information, to bring the product in line with the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are | product                             | no longer                                   |                                  | authorised                                                                                           |
| A20/0006 | submitted by the MAH Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II). Medicinal                                                                                                                                                                                                                                                                                                                                                                           | 18/03/2010                          | 16/09/2010                                  |                                  | Please refer to the Assessment Report: Clopidogrel Hexal-H-1139-A20-06- Assessment Report-Article 20 |

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary authorised                                                                                   |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------|
|          | Article 20 Review                                                                                                                                                                                                                                                                                                                     |                                     |                                             |                                  |                                                                                                      |
| IB/0007  | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                        | 06/08/2010                          | n/a                                         | SPC, Labelling, PL               |                                                                                                      |
| A20/0006 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II). | 18/03/2010                          | 16/09/2010 no                               | longer                           | Please refer to the Assessment Report: Clopidogrel Hexal-H-1139-A20-06- Assessment Report-Article 20 |
| II/0005  | To register a revised version of the ASMF for clopidogrel besilate from the existing active substance manufacturer, introducing changes in the manufacturing process of the active substance. Quality changes Medicinal                                                                                                               | 20/01/2010 product                  | 03/02/2010                                  |                                  |                                                                                                      |
| II/0004  | To introduce a new active substance manufacturer. Quality changes                                                                                                                                                                                                                                                                     | 20/01/2010                          | 03/02/2010                                  |                                  |                                                                                                      |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0003 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 11/09/2009                          | n/a                                         | authorised                       |           |
| IA/0001 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 25/08/2009                          | n/a                                         | longer                           |           |
| IA/0002 | 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                               | 24/08/2009                          | n/a no                                      |                                  |           |

Medicinal product no longer authorised